Sabine Schmid

University Hospital of Bern — Switzerland

Medicine · Health Sciences

25h-index3.4kcitations123works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(43), Lung Cancer Research Studies(27), Cancer Immunotherapy and Biomarkers(17), Occupational and environmental lung diseases(14), Cancer Genomics and Diagnostics(11)

Publications123 total

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort
Journal of Thoracic Oncology·2026Open Access
Data from Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data
2025Open Access
Supplementary Figure from Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data
2025Open Access
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases
Lung Cancer·2025Open Access
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
ESMO Open·2025Open Access
Efficacy of targeted therapy in lung cancer with rare ALK fusions
2025Open Access
P3.18.82 Towards Harmonization of Clinical Care and Promoting Research for Thymic Epithelial Tumors: THETIS (THymic Cancers NETwork in Switzerland)
Journal of Thoracic Oncology·2025
P3.14.11 Real-World Outcomes and Toxicity of First-Line Dual Immunotherapy in Unresectable Pleural Mesothelioma
Journal of Thoracic Oncology·2025
EP.06.83 Prognostic Impact of PD-L1 Expression in a Swiss Cohort ofEGFR-Mutant Non-Small Cell Lung Cancer Patients Treated With First-Line Osimertinib
Journal of Thoracic Oncology·2025
A retrospective analysis exploring the association of pretreatment neutrophil-to-lymphocyte ratio and immune checkpoint inhibitor outcomes in patients with advanced NSCLC and liver metastases
Therapeutic Advances in Medical Oncology·2025Open Access
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Lung Cancer·2025· 2 citedOpen Access
Test performance of a DNA methylation–based liquid biopsy biomarker for detection and classification of pleural mesothelioma (PM).
Journal of Clinical Oncology·2025
Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report
JTO Clinical and Research Reports·2025Open Access
Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
Clinical Lung Cancer·2025· 1 cited
Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting
JTO Clinical and Research Reports·2025Open Access
Expanding first-line options for depression: Protocol of a pragmatic comparative effectiveness trial of yoga vs. behavioral activation (the COMPARE study)
PLoS ONE·2025Open Access
First-line immunotherapy +/- chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small Cell Lung Cancer (NSCLC) with asymptomatic brain metastases
SSRN Electronic Journal·2025Open Access
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
JTO Clinical and Research Reports·2024· 4 citedOpen Access
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
JTO Clinical and Research Reports·2024· 5 citedOpen Access
Outcomes with non-small cell lung cancer and brain-only metastasis
Heliyon·2024· 1 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Martin Früh(17), Sacha I. Rothschild(9), Geoffrey Liu(9), Natasha B. Leighl(8), Dirk Klingbiel(7), Frances A. Shepherd(7), Aurelius Omlin(6), Michael Mark(6), Penelope A. Bradbury(6), Adrian G. Sacher(6), Wolfram Jochum(5), Silke Gillessen(5), Laetitia Mauti(5), Oliver Gautschi(5), Patrizia Froesch(5), Christian Rothermundt(5), Miguel García-Pardo(5), Ming‐Sound Tsao(5), Yannis Metaxas(4), Miklos Pless(4)